Janus Henderson Group Plc - Jul 24, 2024 Form 4 Insider Report for ARCA biopharma, Inc. (ABIO)

Role: 10%+ Owner
Signature: /s/ Michelle Rosenberg, CAO, General Counsel & Company Secretary
Stock symbol: ABIO
Transactions as of: Jul 24, 2024
Transactions value $: $699,165
Form type: 4
Date filed: 7/26/2024, 10:50 AM
Previous filing: Jul 12, 2024
Next filing: Aug 20, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABIO	Common Stock	Purchase	$528K	+165K	+8.72%	$3.20	2.06M	Jul 24, 2024	By Fund	F1
transaction	ABIO	Common Stock	Purchase	$56.6K	+17.8K	+0.87%	$3.18	2.07M	Jul 24, 2024	By Fund	F1
transaction	ABIO	Common Stock	Purchase	$22.3K	+7.06K	+0.34%	$3.16	2.08M	Jul 24, 2024	By Fund	F1
transaction	ABIO	Common Stock	Purchase	$92.3K	+30.2K	+1.45%	$3.05	2.11M	Jul 25, 2024	By Fund	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the "Fund"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serve as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any.

Content

The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the "Fund"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serve as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any.